Spectrum said the FDA had accepted its application for Rolontis, which had shown non-inferiority to Amgen's Neulasta in Phase III testing. However, oncologists expressed mixed opinions about the drug.
Poziotinib did not show an improved response rate among previously treated non-small cell lung cancer patients with a specific genetic mutation, but additional cohorts in the Phase II study are ongoing.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
CEO Joe Turgeon said in an interview that the company aims to focus more on developing drugs for larger, broader and more lucrative oncology markets.